ÂÜÀòÂÒÂ×

A professor at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Frank has held leadership positions with several San Francisco Bay Area biotechnology firms specializing in cancer care, including Cetus Corp and Chiron Corp. In 1992, he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx, he initiated and led drug discovery efforts that led to the approval of Sorafenib for treatment of renal cell cancer and hepatocellular cancer in the United States as well as approval of ONYX-015 in China for treatment of nasopharyngeal cancer. Frank is the author of over 285 scientific publications and holds 20 issued patents. He served as President (2012-2013) for the American Association for Cancer Research. More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI-supported national effort to develop therapies against RAS-driven cancers.